Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Verve Therapeutics Inc
VERVCurrent price
5.97 USD
-0.28 USD (-4.48%)
Last closed
6.15 USD
Company
www.vervetx.com
ISIN
US92539P1012
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
458 031 136 USD
Yield for 12 month
-55.15 %
1Y
3Y
5Y
10Y
15Y
VERV
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 201 Brookline Avenue, Cambridge, MA, United States, 02215
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
26.20 USDP/E ratio
–Dividend Yield
–Current Year
+11 758 000 USD
Last Year
+1 941 000 USD
Current Quarter
+6 865 000 USD
Last Quarter
+6 692 000 USD
Current Year
+6 303 000 USD
Last Year
-4 770 000 USD
Current Quarter
+5 111 000 USD
Last Quarter
+5 025 000 USD
Key Figures VERV
1 year
3 years
5 years
10 years
EBITDA
-219 971 008 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-22.19 %
PEG Ratio
–
Return On Equity TTM
-40.67 %
Wall Street Target Price
26.20 USD
Revenue TTM
24 396 000 USD
Book Value
6.01 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
120.20 %
Dividend Yield
–
Gross Profit TTM
-128 154 000 USD
Earnings per share
-2.46 USD
Diluted Eps TTM
-2.46 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics VERV
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History VERV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation VERV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.97
Price Sales TTM
18.77
Enterprise Value EBITDA
-0.40
Price Book MRQ
0.90
Financials VERV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators VERV
For 52 weeks
4.31 USD
19.34 USD
50 Day MA
5.69 USD
Shares Short Prior Month
17 075 830
200 Day MA
6.74 USD
Short Ratio
11.25
Shares Short
17 872 710
Short Percent
25.20 %
BeatStart